CN Patent

CN113855681B — 贝西沙星在制备用于治疗结核病的药物中的应用

Assigned to Beijing Chest Hospital · Expires 2023-09-05 · 3y expired

What this patent protects

本发明公开了贝西沙星或含有贝西沙星的药物组合物在制备用于预防和/或治疗结核病的药物中的应用，涉及医药技术领域。本发明经过实验证明贝西沙星在体外对分枝杆菌和非结核分枝杆菌具有良好的抑制效果，能够用来制备抗结核分枝杆菌的药物以及用于制备预防和/或治疗结核病的药物，为治疗结核病提供了一种新的药物选择。

USPTO Abstract

本发明公开了贝西沙星或含有贝西沙星的药物组合物在制备用于预防和/或治疗结核病的药物中的应用，涉及医药技术领域。本发明经过实验证明贝西沙星在体外对分枝杆菌和非结核分枝杆菌具有良好的抑制效果，能够用来制备抗结核分枝杆菌的药物以及用于制备预防和/或治疗结核病的药物，为治疗结核病提供了一种新的药物选择。

Drugs covered by this patent

besifloxacin-hydrochloride (BESIFLOXACIN HYDROCHLORIDE)

Patent Metadata

Patent number: CN113855681B
Jurisdiction: CN
Classification: —
Expires: 2023-09-05
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Chest Hospital
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.